QIAGEN N.V.
QGENQIAGEN N.V. is a global provider of sample and assay technologies, serving the life sciences and molecular diagnostics markets. The company specializes in sample preparation, gene detection, and bioinformatics solutions designed for research, clinical, and molecular testing applications. QIAGEN's products facilitate the analysis of biological samples to detect, diagnose, and monitor diseases, making it a key player in advancing personalized healthcare and molecular diagnostics.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| $2.29 | 2026-01-08 | ||
| $1.26 | 2025-01-29 | ||
| $1.04 | 2017-01-25 | ||
| July 10, 2025 | $0.25 | 2025-07-02 | 2025-07-02 |
Dividends Summary
- Total Returned Value: Investors who held QGEN shares during this period received a total of $4.84 per share in dividend income.
- Latest Payout: The most recent dividend of $2.29/share was paid 197 days ago, on July 10, 2025.
- Dividend Growth: Since 2025, the dividend payout has grown by 816.0%, from $0.25 to $2.29.
Company News
The global next-generation sequencing (NGS) market is expected to grow from USD 14.25 billion in 2025 to USD 103.24 billion by 2035, at a CAGR of 21.9%. North America currently dominates with 50% market share, while Asia Pacific is the fastest-growing region. Oncology is the leading application segment, and consumables represent the largest produ...
German life sciences company Qiagen is exploring strategic options including a potential sale, with renewed takeover interest from multiple U.S.-based strategic buyers. The company has engaged advisers as its supervisory board evaluates preliminary approaches. CEO Thierry Bernard's announced departure is seen as removing a key obstacle to a deal....
The Middle East exosomes market is projected to grow from USD 3.07 million in 2024 to USD 20.03 million by 2033, at a CAGR of 23.38%. Growth is driven by increasing adoption of exosome-based diagnostics and therapeutics, rising biomedical R&D investment, and growing demand for liquid biopsy technologies. Key challenges include stringent regulator...
The global reproductive genetics market is projected to grow from USD 7.31 billion in 2025 to USD 16.67 billion by 2032, with a CAGR of 12.5%. Growth is driven by rising demand for genetic testing, preimplantation genetic testing (PGT), and non-invasive prenatal testing (NIPT), though ethical and legal challenges continue to limit expansion. Nort...
The global IVD diagnostic molecule raw enzymes market is projected to grow from USD 2.39 billion in 2024 to USD 4.73 billion by 2034, with a 7.13% CAGR. Key growth drivers include increasing chronic diseases, technological advancements in molecular diagnostics, and rising demand for precision medicine.
